Ernexa Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
Ernexa Therapeutics Inc. (ERNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 113.20% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2019-03-22
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2018-09-30 was 113.90%, a 0.19% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2018-06-30 was 113.09%, a 1.08% decline year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2017-09-30 was 114.12%.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2017-06-30 was 114.33%, a 2.75% increase year-over-year.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2018 was 113.20%, a 0.33% decline from fiscal 2017.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2017 was 113.57%, a 2.30% increase from fiscal 2016.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2016 was 111.02%, a 34.08% increase from fiscal 2015.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2015 was 82.80%, a 3.02% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | 113.20% 10-K · filed 2019-03-22 | ||||
| 2018-09-30 | 113.90% 10-Q · filed 2018-11-09 | 113.20% 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | 113.09% 10-Q · filed 2018-08-06 | 113.09% 10-Q · filed 2018-08-06 | |||
| 2017-12-31 | 113.57% 10-K · filed 2019-03-22 | ||||
| 2017-09-30 | 114.12% 10-Q · filed 2018-11-09 | 114.56% 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | 114.33% 10-Q · filed 2018-08-06 | 114.70% 10-Q · filed 2018-08-06 | |||
| 2017-03-31 | 115.00% 10-Q · filed 2018-05-11 | ||||
| 2016-12-31 | 111.02% 10-K · filed 2018-03-09 | ||||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-08 | 111.02% 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | 111.27% 10-Q · filed 2017-08-04 | 111.02% 10-Q · filed 2017-08-04 | |||
| 2016-03-31 | 110.70% 10-Q · filed 2017-05-04 | 110.71% 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | 82.80% 10-K · filed 2017-03-09 | ||||
| 2015-09-30 | 105.50% 10-Q · filed 2016-11-09 | 82.51% 10-Q · filed 2016-11-09 | |||
| 2015-06-30 | 83.01% 10-Q · filed 2016-08-04 | 82.40% 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | 81.38% 10-Q · filed 2016-05-09 | ||||
| 2014-12-31 | 80.37% 10-K · filed 2016-03-15 | ||||
| 2014-09-30 | 79.77% 10-Q · filed 2015-11-09 | 80.27% 10-Q · filed 2015-11-09 | |||
| 2014-06-30 | 81.42% 10-Q · filed 2015-08-10 | 81.62% 10-Q · filed 2015-08-10 | |||
| 2014-03-31 | 81.77% 10-Q · filed 2015-05-08 | ||||
| 2013-12-31 | 79.82% 10-K · filed 2015-03-27 | ||||
| 2013-09-30 | 77.61% 10-Q · filed 2014-11-07 | 79.58% 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | 79.47% 10-Q · filed 2014-08-14 | 79.80% 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | 80.59% 10-Q · filed 2014-05-15 | 8.06% 10-Q · filed 2013-05-13 | |||
| 2012-12-31 | 95.21% 10-K · filed 2014-03-31 | ||||
| 2012-09-30 | 95.08% 10-Q · filed 2013-11-14 | 95.33% 10-Q · filed 2013-11-14 | |||
| 2012-06-30 | 96.21% 10-Q · filed 2013-08-14 | 96.10% 10-Q · filed 2013-08-14 | |||
| 2012-03-31 | 95.97% 10-Q · filed 2013-05-13 | ||||
| 2011-12-31 | 97.70% 10-K · filed 2013-03-29 | ||||
| 2011-09-30 | 97.58% 10-Q · filed 2012-11-09 | 97.50% 10-Q · filed 2012-11-09 | |||
| 2011-06-30 | 97.63% 10-Q · filed 2012-08-14 | 97.49% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |